UQ1 Stock Overview Develops treatments for patients suffering from rare and other devastating diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for uniQure Historical stock prices Current Share Price US$18.64 52 Week High US$31.11 52 Week Low US$12.29 Beta 0.95 1 Month Change 0% 3 Month Change -4.44% 1 Year Change -40.10% 3 Year Change n/a 5 Year Change n/a Change since IPO -40.77%
Recent News & Updates
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy Nov 21
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS Oct 15
Uniqure N.V. Announces Executive Changes Jul 23
uniQure N.V., Annual General Meeting, Jun 18, 2024 Apr 26
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director Apr 13
uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease Dec 19 See more updates
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy Nov 21
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of Amt-162 for the Treatment Sod1-ALS Oct 15
Uniqure N.V. Announces Executive Changes Jul 23
uniQure N.V., Annual General Meeting, Jun 18, 2024 Apr 26
Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director Apr 13
uniQure N.V. Announces Update on Phase I/II Clinical Trials of Amt-130Gene Therapy for the Treatment of Huntington's Disease Dec 19
uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for Amt-191 Gene Therapy for Fabry Disease Nov 29
uniQure N.V. Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting Oct 25
uniQure N.V. Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy Sep 06
uniQure N.V. Announces Executive Changes Jun 27
uniQure N.V. Highlights Therapeutic Potential of Amt-260 in Refractory Temporal Lobe Epilepsy (Rtle) At Virtual Research & Development Event Nov 30
Second quarter 2022 earnings released: US$0.84 loss per share (vs US$8.68 profit in 2Q 2021) Aug 09
Investor sentiment improved over the past week Jul 11
uniQure N.V. Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease Jun 24
Investor sentiment improved over the past week Jun 23
Chief Operating Officer recently sold €95k worth of stock Jun 22
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review May 26
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review May 25
First quarter 2022 earnings released: US$1.00 loss per share (vs US$0.91 loss in 1Q 2021) May 03
uniQure N.V., Annual General Meeting, Jun 14, 2022 May 02
Insufficient new directors Apr 27
Investor sentiment deteriorated over the past week Apr 21
Investor sentiment deteriorated over the past week Mar 10
CEO & Executive Director recently sold €152k worth of stock Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease Feb 08
CEO & Executive Director recently sold €175k worth of stock Jan 30
Investor sentiment deteriorated over the past week Jan 24
Investor sentiment deteriorated over the past week Dec 22
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease Dec 17
Insufficient new directors Dec 06
Investor sentiment improved over the past week Nov 06
Third quarter 2021 earnings released: US$0.79 loss per share (vs US$1.21 loss in 3Q 2020) Oct 27
President of Research & Development recently sold €271k worth of stock Sep 18
Investor sentiment improved over the past week Sep 09
Second quarter 2021 earnings released: EPS US$8.68 (vs US$0.96 loss in 2Q 2020) Jul 28
Independent Non-Executive Chairman Philip Astley-Sparke has left the company Jun 24
uniQure N.V. Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update Jun 24
Independent Non-Executive Chairman Philip Astley-Sparke has left the company Jun 23
uniQure N.V. Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease Jun 17
uniQure N.V. Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease May 28
No longer forecast to breakeven May 16
uniQure N.V. Presents Hope-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Antibodies to Aav5 Vector May 14
First quarter 2021 earnings released: US$0.91 loss per share (vs US$0.63 loss in 1Q 2020) May 11
uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program Apr 27
CEO, CFO & Executive Director recently sold €152k worth of stock Mar 10
Full year 2020 earnings released: US$2.81 loss per share (vs US$3.11 loss in FY 2019) Mar 02
Revenue misses expectations Mar 02
uniQure N.V. Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease Feb 09
Chief Accounting Officer recently sold €261k worth of stock Jan 30 Shareholder Returns UQ1 DE Biotechs DE Market 7D 0% 3.1% 0.5% 1Y -40.1% -13.8% 7.2%
See full shareholder returns
Return vs Market: UQ1 underperformed the German Market which returned 4.7% over the past year.
Price Volatility Is UQ1's price volatile compared to industry and market? UQ1 volatility UQ1 Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: UQ1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine UQ1's volatility change over the past year.
About the Company uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Show more uniQure N.V. Fundamentals Summary How do uniQure's earnings and revenue compare to its market cap? UQ1 fundamental statistics Market cap €899.25m Earnings (TTM ) -€125.41m Revenue (TTM ) €61.44m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) UQ1 income statement (TTM ) Revenue US$61.43m Cost of Revenue US$125.95m Gross Profit -US$64.52m Other Expenses US$60.87m Earnings -US$125.39m
Last Reported Earnings
Sep 30, 2022
Earnings per share (EPS) -2.68 Gross Margin -105.03% Net Profit Margin -204.12% Debt/Equity Ratio 24.3%
How did UQ1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2022/11/07 18:41 End of Day Share Price 2022/08/10 00:00 Earnings 2022/09/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources uniQure N.V. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Madhu Kumar Baird James Birchenough BMO Capital Markets Equity Research Madhu Kumar B. Riley Securities, Inc.
Show 28 more analysts 